The RITUXAN Co-Pay Card Program is designed to reduce monthly commercial co-payments for eligible patients who have been prescribed RITUXAN. This program makes it easy for you to get patients started on RITUXAN.

How does the program work?

  • Your practice gives eligible patients a brochure with an enclosed RITUXAN Co-Pay Card at the time the diagnosis is made and therapy is chosen
  • Enroll your patients over the phone with RITUXAN Access Solutions prior to their treatment. Before calling, be sure patients have completed the Patient Authorization and Notice of Release Information and Patient Enrollment forms.
  • Your practice will receive confirmation of successful patient enrollment. The patient's co-pay amount will be reduced accordingly.
 

Who is eligible?

Eligible

  • Covered by commercial insurance (non-governmental)
    AND
  • Co-pay for RITUXAN over $100
    AND
  • Annual household income of $100,000 or less
    AND
  • Age 18 years or older
 

Not Eligible

  • Participating in Medicare D, Medicaid Medigap, VA, DoD, and Tricare (or any other federal or statefunded benefit programs)
    OR
  • Uninsured
    OR
  • Current residing or receiving services in Massachusetts
    OR
  • Currently participating in Genentech Access to Care Foundation
 
 

How much does the program cover if my patient is eligible?

Patient Responsibility

The first $100 per month of their RITUXAN co-pay plus 20% of the remaining amount and any additional amount not covered by the program

 

Program pays

Up to 80% of monthly RITUXAN co-pay once patient pays first $100 per month

 

Program limit

Up to $4000 in RITUXAN co-pay support, which must be used within 1 year after patient activates his/her card.

 

How do I explain to patients how this program works?

Eligibility

Be sure to highlight the need for commercial insurance with a co-pay of over $100.

 

Program limits

Program pays up to 80% of monthy co-pay up to $4000 per year. Patients must pay first $100 per month, plus amount not covered by program.

 

Getting started

Activate the card with your patient by calling RITUXAN Access Solutions, where a specialist will assist you in initiating the enrollment process

 
 
RITUXAN: Access Solutions. Treatment made possible.

What about my RITUXAN patients who are not eligible for this program?

At RITUXAN Access Solutions, we are committed to helping all patients access our medicines regardless of their ability to pay. If privately or publicly insured patients have difficulty paying for their RITUXAN co-pay, RITUXAN Access Solutions can refer them to an independent, non-profit organization. Call (888) 249-4918 from 6 AM – 5 PM PT, Monday through Friday or visit www.RITUXANAccessSolutions.com.

 

Indications and Important Safety Information

RITUXAN® (Rituximab) is indicated for the treatment of patients with:

  • Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC)
  • Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
    • Weekly ×4
    • Weekly ×8
    • Bulky disease
    • Retreatment
  • Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
  • Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy
  • Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens

RITUXAN is not recommended for use in patients with severe, active infections.

WARNING: FATAL INFUSION REACTIONS, TUMOR LYSIS SYNDROME (TLS), SEVERE MUCOCUTANEOUS REACTIONS, and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)

Infusion Reactions: RITUXAN administration can result in serious, including fatal, infusion reactions. Deaths within 24 hours of RITUXAN infusion have occurred. Approximately 80% of fatal infusion reactions occurred in association with the first infusion. Carefully monitor patients during infusions. Discontinue RITUXAN infusion and provide medical treatment for Grade 3 or 4 infusion reactions.

Tumor Lysis Syndrome (TLS): Acute renal failure requiring dialysis with instances of fatal outcome can occur in the setting of TLS following treatment of non-Hodgkin’s lymphoma (NHL) with RITUXAN monotherapy.

Severe Mucocutaneous Reactions: Severe, including fatal, mucocutaneous reactions can occur in patients receiving RITUXAN.

Progressive Multifocal Leukoencephalopathy (PML): JC virus infection resulting in PML and death can occur in patients receiving RITUXAN.

RITUXAN has also been associated with other serious and/or fatal adverse reactions. These include

  • hepatitis B reactivation with fulminant hepatitis; hepatic failure resulting in death
  • serious, including fatal, bacterial, fungal, and new or reactivated viral infections
  • cardiovascular events, including serious or life-threatening cardiac arrhythmias
  • severe, including fatal, renal toxicity
  • abdominal pain, bowel obstruction and perforation, in some cases leading to death, can occur in patients receiving RITUXAN in combination with chemotherapy

Additional Important Safety Information

  • The most common adverse reactions of RITUXAN (incidence ≥25%) observed in clinical trials of patients with NHL were infusion reactions, fever, lymphopenia, chills, infection, and asthenia. The incidence of infusion reactions was highest during the first infusion (77%) and decreased with each subsequent infusion. These infusion reactions typically resolved with slowing or interruption of the infusion and with supportive care. The most frequent Grade 3 or 4 adverse reactions observed in NHL were cytopenias, including lymphopenia
  • The most common adverse reactions of RITUXAN (incidence ≥25%) observed in clinical trials of patients with CLL were infusion reactions and neutropenia. Infusion-related adverse reactions occurring during or within 24 hours of the start of infusion included nausea, pyrexia, chills, hypotension, vomiting, and dyspnea. Most patients treated with R-FC experienced at least one Grade 3 or 4 adverse reaction. The Grade 3 or 4 adverse reactions observed more frequently with R-FC compared with FC alone were neutropenia, leukopenia, febrile neutropenia, thrombocytopenia, infusion reactions, pancytopenia, hypotension, and hepatitis B
  • In clinical trials, CLL patients 70 years of age or older who received R-FC had more Grade 3 and 4 adverse reactions compared with younger CLL patients who received the same treatment

For additional safety information, please see the full prescribing information, including BOXED WARNINGS and Medication Guide.

Attention Healthcare Provider: Provide Medication Guide to patient prior to RITUXAN infusion.


Terms & Conditions

Patient:
Use of the card does not obligate you to use or continue using any specific product or provider. If you have any questions regarding your eligibility or benefits, or if you wish to discontinue your participation, contact RITUXAN Access Solutions at 1 (888) 249-4918 weekdays, 6 AM to 5 PM PST. You may receive additional program information about the RITUXAN Co-Pay Card Program once you are enrolled.

Physician:
For questions regarding enrollment, claim transmission, patient eligibility, or other issues, contact RITUXAN Access Solutions at 1 (888) 249-4918 weekdays, 6 AM to 5 PM PST.

General:
No person or entity may seek reimbursement from any third-party payer for any amount provided using the card program. Genentech USA, Inc. and Biogen IDEC Inc. reserves the right to deny payment under the card to anyone deemed ineligible in accordance with the stated program criteria.